LN-235Homo sapiens (Human)Cancer cell line
Also known as: LN235, LN 235
🤖 AI SummaryBased on 6 publications
Quick Overview
Human glioblastoma cell line with TP53 and PTEN mutations.
Detailed Summary
LN-235 is a human glioblastoma cell line derived from a 38-year-old male patient. It is characterized by mutations in the TP53 and PTEN genes, which are critical in tumor suppression pathways. The cell line exhibits a fibroblastic morphology and has been used in studies examining genetic alterations and their implications in glioma development. LN-235 has been part of research on co-alterations of tumor suppressor genes and their role in glioma progression. It is also utilized in studies assessing the genetic diversity and ancestry of cancer cell lines, highlighting its relevance in understanding tumor heterogeneity and therapeutic responses.
Research Applications
Genetic analysis of tumor suppressor gene mutationsStudy of co-alterations in tumor suppressor pathwaysAssessment of genetic diversity in cancer cell linesInvestigation of tumor heterogeneity and therapeutic responses
Key Characteristics
TP53 mutation at codon 176/176PTEN mutation with splice (del. exon 5)Fibroblastic morphologyExpression of GFAP (glial fibrillary acidic protein)
Generated on 6/20/2025
Basic Information
| Database ID | CVCL_3957 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Brain, right fronto-temporal lobe |
Donor Information
| Age | 38 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Astrocytoma |
|---|---|
| Lineage | CNS/Brain |
| Subtype | Astrocytoma |
| OncoTree Code | ASTR |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000591_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Tyr163Cys (c.488A>G) | Unspecified | - | PubMed=12884349 |
| MutationSimple | TP53 | p.Cys176Ser (c.526T>A) | Homozygous | - | Unknown, Unknown, PubMed=10700188, PubMed=8194712 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
11,12
D13S317
9
D16S539
11
D18S51
13,16
D21S11
29,32.2
D3S1358
15,17
D5S818
11,12
D7S820
10,12
D8S1179
14,15
FGA
22
Penta D
11,12
Penta E
14,15
TH01
7,9
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Hamou M.-F., Delorenzi M., Hegi M.E.
Neuro-oncol. 14:701-711(2012).
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Van Meir E.G.
Brain Pathol. 9:469-479(1999).
The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas.
Rimoldi D., Romero P., Carrel S.
Int. J. Cancer 54:527-528(1993).
Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas.
Diserens A.-C., Van Meir E.G.
Cancer Res. 53:5345-5349(1993).